UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1235-10
Program Prior Authorization/Notification
Medication Ingrezza® (valbenazine)
P&T Approval Date 11/2017, 11/2018, 11/2019, 11/2020, 6/2021, 6/2022, 6/2023, 10/2023,
4/2024, 4/2025
Effective Date 7/1/2025
1. Background:
Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment
of adults with tardive dyskinesia and chorea associated with Huntington’s disease.1
2. Coverage Criteriaa:
A. Tardive Dyskinesia
1. Initial Authorization
a. Ingrezza will be approved based on the following criterion:
(1) Diagnosis of tardive dyskinesia
Authorization will be issued for 12 months.
2. Reauthorization
a. Documentation of positive clinical response to Ingrezza therapy
Authorization will be issued for 12 months.
B. Chorea associated with Huntington’s disease
1. Initial Authorization
a. Ingrezza will be approved based on the following criterion:
(1) Diagnosis of chorea associated with Huntington's disease
Authorization will be issued for 12 months.
2. Reauthorization
a. Documentation of positive clinical response to Ingrezza therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
© 2025 UnitedHealthcare Services Inc.
1
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits, Step Therapy, and/or Medical Necessity may be in place.
4. References:
1. Ingrezza [package insert]., San Diego, CA: Neurocrine Biosciences, Inc.; February 2025
Program Prior Authorization/Notification - Ingrezza (valbenazine)
Change Control
11/2017 New program
11/2018 Annual review. No changes to clinical coverage criteria. Updated
reference.
11/2019 Annual review. No changes to clinical coverage criteria. Updated
reference.
11/2020 Annual review. Updated reference.
6/2021 Added Ingrezza exclusion statement. Updated reference.
6/2022 Annual review. No updates.
6/2023 Annual review. Updated reference.
10/2023 Added criteria for chorea associated with Huntington's disease. Updated
background and reference.
4/2024 Removed notation that Ingrezza is typically excluded.
4/2025 Annual review. No changes to clinical coverage criteria. Updated
reference.
© 2025 UnitedHealthcare Services Inc.
2